Active	Status	Sponsor type	Region	Phase	Filter
18 Active 3 Inactive 21 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

18 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Levin, Richard
NCT03899467: The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC	Completed	2	61	US	GT0918, proxalutamide, androgen receptor antagonist	Suzhou Kintor Pharmaceutical Inc,	Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	03/22	09/22
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Henry, Gerard
NCT05287438: Next Generation Sequencing Versus Traditional Cultures for Clinically Infected Penile Implants: Impact of Culture Identification on Outcomes	Recruiting	N/A	40	US	Next-Generation DNA Sequencing, NGS, Standard Culture	MicroGenDX	Penile Implantation, Infections	10/23	10/24
NCT06217328: RESTORE: An RCT to Evaluate the Efficacy of the Revi System	Recruiting	N/A	150	US	Revi System Treatment, Revi System - Delayed Activation	BlueWind Medical	Urinary Urge Incontinence	05/25	05/27
NCT06511141: Sacral Neuromodulation for Male Overactive Bladder (MOAB)	Recruiting	N/A	120	US	Axonics SNM System	Axonics, Inc.	Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy	12/26	03/27
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
George, Arvin
PRESERVE, NCT04972097: Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue	Active, not recruiting	N/A	121	US	Irreversible Electroporation, The NanoKnife System	Angiodynamics, Inc.	Prostate Cancer	07/24	07/24
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Fraiman, Mitchell
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Hansen, Danielle
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Vs Anti-Arrhythmic Drug (AAD) Therapy As a First Line Treatment for Persistent Atrial Fibrillation	Recruiting	N/A	520	Europe, Canada, US, RoW	FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone	Boston Scientific Corporation	Persistent Atrial Fibrillation	12/25	12/27
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Wright, Katie
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent	Terminated	3	105	US	VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga	Veru Inc.	Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer	05/23	05/23
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following	Recruiting	3	364	Canada, US	Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM	CG Oncology, Inc.	Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma	01/28	01/30
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer	Terminated	1b/2	24	US	VERU-100	Veru Inc.	Advanced Prostate Adenocarcinoma	01/23	01/23
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Ayenew, Michael
#HOPE4KIDNEY, NCT05820087: The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy	Recruiting	N/A	68	US	HistoSonics Edison System, Histotripsy	HistoSonics, Inc.	Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor, Tumor, Benign	12/24	12/29
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29
Bowers, Michaelina
VAPOR 2, NCT05683691: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer	Recruiting	N/A	400	US	Vanquish System	Francis Medical Inc.	Prostate Cancer	04/27	04/29